Context: Studies of the clinical and immunological features of autoimmune Addison disease (AAD) are needed to understand the disease burden and increased mortality.
A utoimmune Addison disease (AAD) is a rare disease caused by an immunological attack on the adrenal cortex, with a frequent finding of autoantibodies toward 21-hydroxylase (21-OH), a steroid enzyme expressed in the adrenal cortex (1) . The autoimmune attack leads to destruction of the adrenal glands, resulting in deficiency of the adrenal steroid hormones. Untreated, AAD is lethal; however, today's hormonal replacement therapy enables survival. Treatment includes glucocorticoid and mineralocorticoid replacement, although the benefit of androgen replacement is debatable (2) . The ideal glucocorticoid replacement therapy would mimic the endogenous circadian cortisol rhythm, but this is not possible to achieve with the current conventional oral replacement regimens that generate periods of supraphysiological and infraphysiological cortisol levels (3) . During recent years, a modified-release hydrocortisone tablet with a combination of an immediate-release coating and an extended-release core was introduced with the aim of better replicating the diurnal cortisol profile (4) .
Concern exists that patients tend to be overtreated with glucocorticoids, with negative cardiovascular and metabolic consequences (e.g., impaired glucose tolerance and dyslipidemia) (5-7). Neither of the 2 natural mineralocorticoids, aldosterone and 11-deoxycortison, are suitable for replacement therapy; hence, the synthetic corticosteroid fludrocortisone is used. Today's replacement therapy, which is far from physiological, might contribute to the increased mortality and morbidity reported for patients with AAD (8) .
AAD is commonly associated with other organ-specific autoimmune disorders and autoimmune polyendocrine syndrome (APS). APS-1 is a very rare monogenic disorder caused by mutations in the autoimmune regulator (AIRE) gene (9) . APS-1 is characterized by the triad chronic mucocutaneous candidiasis, hypoparathyroidism, and AAD. APS-2 is a much more common and genetically complex entity characterized by $2 concurrent autoimmune endocrinopathies [(e.g., AAD, autoimmune hypo-or hyperthyroidism, and type 1 diabetes (T1DM) (10) ]. Autoantibodies directed against 21-OH are an excellent diagnostic marker of AAD, and autoantibody screening can disclose the presence or predict the development of other autoimmune diseases and is consequently an important tool in monitoring patients (11) .
Owing to the rarity of AAD, most studies have been too small to determine the natural course of the disease and associated comorbidities. The Swedish Addison Registry (SAR) is the world's largest collection of clinical data and blood samples from patients with AAD, to date containing 813 patients. Using the SAR, we performed a clinical and immunological characterization of 660 AAD patients included in the registry from 2008 to 2014; estimated to constitute 50% of all AAD patients in Sweden (12) . Our aim was to obtain deeper insights into autoimmune comorbidities, immunological profile, replacement therapy, and cardiovascular risk factors.
Patients and Methods

Patients
In 2008, a national network of pediatric and adult endocrinologists in Sweden was established, with the aim of studying the clinical, immunological, and genetic aspects of primary adrenal insufficiency. To be included, patients must fulfill the general diagnostic criteria for primary adrenal insufficiency (13) . Typically, the diagnostic test includes measurement of serum cortisol, which in patients is usually less than the normal range, and plasma adrenocorticotropic hormone, which will be clearly increased. In disputable cases, a Synacthen ® (tetracosactide) stimulation test should be performed to establish the diagnosis. Detection of 21-OH autoantibodies in serum confirms an autoimmune etiology. Physicians record data on height and weight, year of diagnosis, probable cause of primary adrenal insufficiency, concomitant autoimmune disorders, cardiovascular risk factors [hypertension, hyperlipidemia, and type 2 diabetes mellitus (T2DM)], medication, and family history on a registration form. Blood samples are collected, and aliquots of sera and DNA are stored frozen in a biobank until analysis. The biobank and patient data represent the SAR (available at http://www.addisonregistret.se). The present study included the data from patients in the SAR from 2008 to 2014 (Fig. 1) . Because the endocrinologists engaged in the study primarily work at university hospitals, we have reason to believe that inclusion from these sites was larger than that from smaller local hospitals.
All registration forms were thoroughly checked, and missing data were obtained from the medical records. Patients with documented nonautoimmune primary adrenal insufficiency and patients with a previously established APS-1 diagnosis or clinical features resembling APS-1 were excluded. In total, 660 patients with verified (21-OH autoantibody positive) or probable AAD were identified and included in the study.
Ethics
The regional ethics committee approved the present study (permit 2008/296-31/2), and all patients provided written informed consent.
Autoantibody analyses
The following well-characterized autoantibodies were selected as disease markers in the SAR cohort: 21-OH, 17a-hydroxylase (17a-OH), and aromatic L-amino acid decarboxylase (AADC) for Addison disease. Thyroid peroxidase (TPO) autoantibodies for hypothyroidism, glutamic acid decarboxylase 65 (GAD65), and islet antigen-2 (IA-2) autoantibodies for T1DM. Parietal cell autoantibodies for pernicious anemia, side chain cleavage enzyme (SCC) autoantibodies for autoimmune hypogonadism, tissue transglutaminase 2 (TGM2) autoantibodies for celiac disease, SRY (sex-determining region Y)-box 10 (SOX10) autoantibodies for vitiligo, interferon-v (IFNv), interferon-a4 (IFNa4), and interleukin-22 (IL-22) autoantibodies for APS-1. Full-length complementary DNA clones of 21-OH, 17a-OH, AADC, SCC, SOX10 (SC123774; OriGene, Rockville, MD), IFNv (RC222484; OriGene), IFNa4 (SC304903; OriGene), and IL-22 (RC209995; OriGene) were used for in vitro transcription and translation to generate 35 S-radiolabeled recombinant protein antigens using the TnT system (Promega, Madison, WI) in accordance with the manufacturers' protocol. Of 35 S-radiolabeled recombinant protein antigens, 20,000 cpm were used in each well for immunoprecipitation with patient or blood donor sera in 96-well filtration plates (EMD Millipore, Darmstadt, Germany). A total of 213 healthy blood donors served as negative controls and were tested for all the antigens. Serum samples from patients and controls were analyzed in duplicates for 21-OH, and in single samples at first, followed by analysis in duplicates for positive samples for 17a-OH, AADC, SCC, SOX10, IFNv, IFNa4, and IL-22. The radioactivity of the immunoprecipitated material was measured with a liquid scintillation counter (Wallac 1450 MicroBeta; Perkin-Elmer, Shelton, CT). For all patients and controls, an index value was calculated as follows: [(cpm in the unknown sample 2 cpm in negative standard)/(cpm in the positive standard 2 cpm in the negative standard)] 3 100. APS-1 patients with known strong reactivity to the antigen were used as positive controls, and 4% bovine albumin served as the negative control on each plate. The upper limit of the normal range was defined as the mean index value for blood donors plus 3 standard deviations. For the 21-OH autoantibody analysis, the cutoff value was set to obtain the maximal accuracy cutoff value, based on the results from a recent interlaboratory study (14) . press.endocrine.org/journal/jcemCommercial kits were used to assay antibodies against TPO (RSR Ltd., Cardiff, UK), IA-2 (Medipan GmbH, Berlin, Germany), GAD65 (Medipan GmbH), TGM2 (Bio-Rad Laboratories, Hercules, CA; Phadia, Uppsala, Sweden), deamidated gliadin (Bio-Rad Laboratories; Phadia), and parietal cell (Orgentec Diagnostika, Mainz, Germany). All patients were tested for total immunoglobulin A (IgA). For patients with IgA deficiency (IgA ,0.07 g/L), IgG TGM2 was analyzed. For analysis of endomysium autoantibodies, monkey esophagus was stained with patient serum (1:10 to 1:640) and detected with fluorescein isothiocyanate-conjugated antihuman IgA antibody (Dako, Glostrup, Denmark).
Analyses of cardiovascular risk factors
The Northern Sweden MONICA (monitoring of trends and determinants of cardiovascular disease) study is a populationbased study of the trends in mortality and morbidity of cardiovascular disease and risk factors in the 2 northernmost counties in Sweden (15) . A total of 3594 unique individuals from the MONICA surveys of 2004 (n = 1865) and 2009 (n = 1729) were used as a control population for the SAR cohort to compare the prevalence of cardiovascular risk factors, including body mass index (BMI), hypertension, hyperlipidemia, and T2DM. The MONICA survey included individuals aged 25 to 74 years; thus, patients in the SAR aged ,25 or .74 years were excluded (n = 89) to allow comparisons between the SAR and MONICA data ( Fig. 1) . To counteract inclusion of AAD patients with clinically nonovert APS-1, which would possibly profoundly distort the statistical significance, we excluded 22 patients from the SAR cohort with an APS-1 suggestive autoantibody profile [i.e., autoantibodies against IFNv (n = 16), IFNa4 (n = 4), and/or IL-22 (n = 3)], resulting in a study group of 549 patients ( Fig. 1) .
In the SAR cohort, the presence of hypertension, hyperlipidemia, or T2DM was defined as an affirmative answer by the reporting physician for the presence of the condition or medical treatment of the condition. In the MONICA cohort, the presence of hypertension was defined as affirmative answers to the following 2 questions: "Have you at any time been notified about hypertension by a doctor or nurse?" and "If yes, have you during the past 2 weeks taken any medications for hypertension?" (missing data = 82). Similarly, hyperlipidemia was defined as an affirmative answer to the following question: "During the past 2 weeks have you taken any medication prescribed by a physician for lowering cholesterol or blood lipids" (missing data = 31). All individuals with diabetes mellitus in the MONICA cohort were reviewed and classified as having T1DM or T2DM, as previously described (16) . The BMI was calculated using the height and weight recorded on the registration form, with 8 missing data in the SAR cohort and 25 missing data in the MONICA cohort.
Statistical analyses
t Tests were performed to investigate the differences between subgroups for the continuous variables. x 2 tests were performed to investigate differences between subgroups in frequencies, and Fisher's exact test was used instead of the x 2 test if the data points were insufficient. P values for the analyses including the 21-OH autoantibody index were calculated with logistic regression analysis. Analyses were also performed to compare subgroups in the SAR, investigating differences with regard to sex and 21-OH autoantibody-positive and 21-OH autoantibodynegative patients. All statistical analyses were performed using the SAS, version 9.4 (SAS Institute, Cary, NC), and Prism, version 6 (GraphPad, La Jolla, CA), software. For comparisons of the SAR and MONICA cohorts, we used linear regression for BMI and binary logistic regression with hypertension, hyperlipidemia, and T2DM as dependent variables, AAD as the independent variable, and sex and age as covariates (SPSS, version 23.0; IBM Corp., Armonk, NY). For all analyses in the present study, statistical significance was accepted if P , 0.05.
Results
Clinical characteristics of the SAR cohort
The SAR cohort included 660 AAD patients ( Fig. 1) , of whom 60% were female, and 2% were children ,18 years old (Table 1) . The age at diagnosis varied from 0 to 79 years. The mean age at diagnosis was older for females (36.8 6 14.0 years) than for males (31.1 6 13.6 years; P , 0.0001). Thirty-eight percent of the patients had isolated AAD, and 62% had a diagnosis of $1 associated autoimmune disease. Female patients had an average of 1.03 6 0.91 associated autoimmune diseases compared with 0.64 6 0.77 for male patients (P , 0.0001; Fig. 2 ). The number of associated diseases did not correlate with patient age at AAD diagnosis. The most frequently associated disease among both females and males was hypothyroidism, which was more common among females than males (P , 0.0001). Also, hyperthyroidism (P = 0.0028), hypogonadism (P = 0.0015), and alopecia (P = 0.045) were more frequent among females than males (Table 1) .
Replacement therapy
All patients received glucocorticoid replacement therapy; 89% used conventional hydrocortisone tablets, and 8% used hydrocortisone modified-release tablets (Plenadren ® ), with an immediate-release coating combined with an extended-release core ( Table 2 ). The mean daily dose for patients with conventional hydrocortisone treatment (n = 584) was 28.1 6 8.5 mg/d (missing data = 1), divided into 1 (13%), 2 (50%), 3 (33%), or 4 (3%) daily doses (missing data = 8). When the glucocorticoid replacement doses were normalized to the body surface and recalculated to the hydrocortisone equivalent dose, the mean dose was 14. No difference was found in the hydrocortisone equivalent dose between the sexes. Patients receiving the modified-release hydrocortisone tablets (n = 52) had a 2.8-mg/m 2 /d lower mean total hydrocortisone equivalent dose than patients with conventional hydrocortisone tablets [95% confidence interval (CI), 1.56 to 4.04; P , 0.0001]. A statistically significant positive association was observed between the hydrocortisone equivalent dose and the incidence of hypertension (P = 0.046) but not for hyperlipidemia or T2DM.
Mineralocorticoid replacement was used by 89% of the patients, with a median fludrocortisone dose of 1 mg/d (range, 0.014 to 1.0 mg/d). No sex or age differences were found in the prevalence of fludrocortisone replacement (P = 0.96) or daily fludrocortisone dose (P = 0.56). The hydrocortisone dose was not substantially different in AAD patients with or without mineralocorticoid replacement. In addition, no association was found between the daily fludrocortisone dose and the prevalence of hypertension, hyperlipidemia, or T2DM. More females (28 of 393; 7%) than males (5 of 267; 2%) received androgen replacement therapy (P = 0.015).
Autoantibody profile
The proportion of 21-OH autoantibody-positive AAD patients was 83.3%. Males and females with 21-OH b A complete list of diseases considered autoimmune is available in the supplemental material.
c Of the 17 patients with autoantibodies against transglutaminase, 13 had antigliadin antibodies, and 10 also had endomysium autoantibodies.
doi: 10.1210/jc.2016-2522 press.endocrine.org/journal/jcemautoantibodies both had a shorter disease duration than 21-OH autoantibody-negative patients (mean, 15.6 vs 23.9 years; P , 0.0001). A relevant association was found between the decrease in 21-OH autoantibody level and the AAD duration (Fig. 3) . A positive association was seen between the presence of 21-OH autoantibodies and hypothyroidism (P = 0.0330) and pernicious anemia (P = 0.0037). Also, the presence of 21-OH autoantibodies correlated positively with the presence of autoantibodies against TPO (P = 0.0049) and parietal cell autoantibodies (P = 0.0130). The autoantibody frequency stratified by sex and 21-OH autoantibody status is presented in Table 1 . Clinically overt coexisting autoimmune disease was significantly associated with autoantibodies against TPO for hypothyroidism, GAD65 and/or IA-2 for T1DM, parietal cell autoantibodies for pernicious anemia, TGM2 for celiac disease, and SCC for hypogonadism in females (P , 0.0001). However, more patients had positive autoantibody findings than manifested the corresponding clinical disease (e.g., 374 patients had TPO autoantibodies but only 264 had overt hypothyroidism, 153 patients had GAD65 autoantibodies but only 71 had overt T1DM, and 217 patients had parietal cell autoantibodies but only 69 had pernicious anemia). In addition, only 5 of the 17 patients with TGM2 autoantibodies were reported to have a clinical diagnosis of celiac disease, suggesting that 12 of the patients with TGM2 autoantibodies had undiagnosed disease. Of the 660 patients, 9 (1.4%) had IgA deficiency. Also, 22 patients had autoantibodies against IFNv (n = 16), IFNa4 (n = 4), and/or IL-22 (n = 3), with 1 patient having autoantibodies against both IFNv and IFNa4. Thus, all 22 patients had findings suggestive for APS-1. However, none of these patients had hypoparathyroidism or mucocutaneous candida infection.
Cardiovascular risk factors
The SAR had a significantly greater proportion of females (59.2%) than did the control population (50.9%; P , 0.0001). The mean age did not differ between the 2 cohorts.
The BMI was lower in the patients than in the controls, with mean difference of 1.28 kg/m 2 adjusted for age and ; P , 0.0001; Table 3 ). The patients also had a significantly lower prevalence of hypertension than the controls, but no differences were found for hyperlipidemia or T2DM (Table 3 ). Extracting only the SAR patients with 21-OH autoantibodies (n = 461), the effects were very similar, with a substantially lower BMI and lower prevalence of hypertension in the SAR patients, with a mean BMI difference of 1.23 kg/m 2 adjusted for age and sex (95% CI, 0.78 to 1.68 kg/m 2 ; P , 0.0001) and odds ratio (OR) for hypertension of 0.73 (95% CI, 0.55 to 0.97; P = 0.027). No statistically significant interactions were seen between AAD and sex or AAD and age and the prevalence of these cardiovascular risk factors, except for a significant interaction between AAD and age on the prevalence of hyperlipidemia. AAD patients aged ,65 years had an increased prevalence of hyperlipidemia (OR, 1.54; 95% CI, 1.04 to 2.29; P = 0.031). However, no statistically significant effect of AAD was found for patients aged $65 years (OR, 0.70; 95% CI, 0.42 to 1.15; P = 0.160). Excluding patients with T1DM from both groups, the interaction effect of age on hyperlipidemia was lost (P = 0.26).
Discussion
We have provided updated sex-based data regarding autoimmune comorbidities, autoantibody profiles, replacement therapy, and, in such a large AAD cohort, cardiovascular risk factors.
In alignment with previous observations, females were in majority in the SAR cohort and had received a diagnosis of AAD at an older age than males (17) (18) (19) (20) . Of the 660 AAD patients in our study, 637 (97%) presented with at least 1 additional autoimmune disease or tested positive for any of the autoantibodies analyzed (other than anti-21-OH). The most frequent concomitant diseases were hypothyroidism, T1DM, pernicious anemia, and hyperthyroidism, in concordance with studies from Norway (21), Italy (22) , and the United Kingdom (23). We did find an association between clinical overt disease b Data missing for 25.
c Linear regression adjusted for age and sex. press.endocrine.org/journal/jcemand autoantibody status. However, a considerable proportion of the patients had autoantibodies without a clinical diagnosis of the corresponding disease. These data suggest surveillance for autoimmune comorbidities should be performed using thyroid function, TPO autoantibody, blood count, cobalamin, glucose, and hemoglobin A1c measurements. The prevalence of celiac disease in Europe is approximately 1% but considerable geographical variation exists, with Sweden having one of the greatest at 1.8% (24) (25) (26) . Among patients with AAD, a prevalence of 7.9% has been reported (27) , and routine screening with TGM2 autoantibodies has been suggested. The actual number of patients with celiac disease in our AAD cohort could potentially have been #27 (4.1%). IgA deficiency is the most common primary immunodeficiency, with a frequency of 1 in 600 in whites (0.17%) (28, 29) . It has been linked to a number of autoimmune diseases, in particular, celiac disease and T1DM (30) . In the present study, 1.4% of the patients had IgA deficiency, results comparable to those from the Italian study (1.8%) (22) .
In our study, the prevalence of vitiligo and alopecia was somewhat lower than previously reported (21, 22) . We did not find any male preponderance regarding T1DM, in contrast to the data from the general population and the Norwegian cohort (31). Our female patient group was more prone to autoimmune comorbidity than were the males with AAD, in agreement with general population data and the 2 previous largest cohort studies of primary adrenal insufficiency from Norway and Italy (21, 22) . Hyperthyroidism and alopecia have not previously been reported to have a female preponderance. All the AAD patients who tested positive for SCC autoantibodies in our study were females, as were most patients with 17a-OH autoantibodies. In the Norwegian material, more females than males also had autoantibodies against SCC and 17a-HO. Of 18 females with self-reported premature menopause, 13 had SCC autoantibodies (21) . Autoimmune oophoritis might be an important, but clinically unnoticed, underlying cause of the reduced parity observed in females with AAD. Thus, we would suggest a robust monitoring policy and fertility-preserving actions to prevent infertility (32) .
Eighty-three percent of the SAR patients had autoantibodies against 21-OH, in accordance with previous reports (20) (21) (22) 33) . The presence of 21-OH autoantibodies is an excellent AAD diagnostic marker, and the detection method used was well evaluated in a previous study by Falorni et al. (14) . Serum 21-OH autoantibodies were often detectable decades after the AAD diagnosis. Nevertheless, although weak, an important association was found between the reduction in 21-OH autoantibody levels and disease duration, as previously reported (18).
Overall, the frequency of GAD65 and transglutaminase IgA autoantibodies in the SAR cohort was similar to that found in Norway (21) . Six patients (1%) in our cohort had anti-AADC antibodies. Their function in AAD remains unclear, although they have been proposed to be associated with autoimmune hepatitis and vitiligo in APS-1 patients (11). However, none of these 6 patients had vitiligo. A similar frequency of AADC autoantibodies has previously been reported among Norwegian AAD patients (21) .
Treatment recommendations have shifted from glucocorticoids with long biological activity (prednisolone or prednisone or dexamethasone) toward more shortacting activity (hydrocortisone and cortisone acetate) to avoid overtreatment and enable the physiological diurnal pattern. Our study has shown that in contemporary Swedish AAD patients, long-acting glucocorticoids were used very sparsely. Also, in Norway, Italy, and the United Kingdom, most patients have been reported to primarily use short-acting glucocorticoids but the choice between hydrocortisone or cortisone acetate could vary depending on which glucocorticoid is registered in the country and thus available. For example, in Norway, cortisone acetate is the only registered natural glucocorticoid available. The mean daily hydrocortisone dose of 28.1 mg/d in the present study was, however, slightly greater than 15 to 25 mg/d, the current generally recommended dose (34). We believe that over time a reduction has occurred in the daily hydrocortisone doses in Sweden (17) . Very few data exist on the actual doses used in AAD cohorts and accordingly whether patients and physicians have adhered to the contemporary recommendations. The Norwegian study reported a mean hydrocortisone equivalent daily dose of 32.4 mg/d (21) , and lower doses have been reported from the United Kingdom (mean daily hydrocortisone dose, 24.0 6 5.5 mg/d) and Italy (mean hydrocortisone equivalent daily dose, 25.2 mg/d) (22, 23) . A median hydrocortisone dose of 23.8 mg/d has been observed in South Africa (6). In our study, patients receiving modified-release hydrocortisone had a significantly lower mean hydrocortisone equivalent dose than that of patients taking the conventional hydrocortisone replacement. The exact percentage of patients using a mineralocorticoid replacement was not stated in the previous larger cohort studies from Norway and Italy, only that, just as in the present study, it was used by most of the patients (21, 22) . In the U.K. cohort, all patients were receiving fludrocortisone treatment, and androgen replacement therapy was much more common (29%) than in the Swedish (5%) and Norwegian (5%) cohorts (23) .
Excess glucocorticoid exposure adversely affects several risk factors for cardiovascular disease such as hypertension, obesity with abdominal fat distribution, and altered glucose metabolism (35, 36) . Studies of patients with secondary adrenal insufficiency have shown that hydrocortisone doses $20 mg are associated with an increase in cardiovascular risk factors (37, 38) . Large population-based registry studies of Swedish patients with primary adrenal insufficiency have shown an increased mortality risk with cardiovascular disease as the leading cause of death (17, 39) . Furthermore, AAD patients use more cardiovascular medicines than the background population (12) . However, the use of oral antidiabetic agents did not seem to be more frequent among AAD patients (5, 6, 23) .
In the present study, none of the important cardiovascular risk factors (i.e., obesity, hypertension, hyperlipidemia, or T2DM) was more prevalent among the AAD patients than among the control cohort. The prevalence of T2DM in the MONICA cohort was thoroughly validated through cross-checks with the Swedish national registers, systematic review of the medical records, and analyses of glutamic acid decarboxylase autoantibodies and C-peptide (16) . Thus, these data are considered very well validated and highly comparable to physician-reported occurrences of T2DM from the SAR. The data on hypertension and hyperlipidemia should be interpreted with some caution, considering these data were patient reported in MONICA and physician reported in the SAR. However, previous studies have shown that the validity of self-reported medication for hypertension and hyperlipidemia is reasonably high, with high specificity, and, if anything, slightly underestimated (40) . However, this might be dependent on the context and population characteristics studied (41) . We have previously shown very high validity for self-reported usage of lipid-lowering drugs within the Northern Sweden MONICA cohort (42) .
We observed an association between a higher hydrocortisone equivalent dose and greater incidence of hypertension in the AAD cohort, which might suggest that glucocorticoid overdosing is a risk factor. In line with previous epidemiological results, AAD patients aged ,65 years had an increased prevalence of hyperlipidemia (12) . A possible interpretation is that in patients aged .65 years, other, more relevant age-related factors for hyperlipidemia, overshadow the effect of AAD. However, it is also possible that a low threshold for the diagnosis and treatment of mildly elevated cholesterol in patients with concurrent diabetes influenced the results, because this interaction effect was no longer seen after exclusion of patients with T1DM.
A substantial proportion of the SAR patients did not receive fludrocortisone replacement, and among the patients who did, the mean daily dose might have been too low for appropriate effects (13, 43) . The explanations for these findings are not clear, because the use was not significantly influenced by sex, age, or the presence of hypertension.
In summary, the present nationwide study contains the largest AAD patient cohort to date and represents, by estimate, 50% of all patients with AAD in Sweden. Most patients had 21-OH autoantibodies, which are good markers of AAD and might be present in the circulation even decades after the diagnosis. Many patients have autoantibodies without reported disease, highlighting the necessity for close monitoring of developing autoimmune comorbidities. Most patients currently use the shortacting hydrocortisone. Although the mean daily dose was still greater than the general recommendations, we did not find evidence of AAD patients having an increased prevalence of obesity, hypertension, hyperlipidemia, or T2DM. However, we did observe an association between a greater hydrocortisone equivalent dose and a greater incidence of hypertension.
